Salute e Benessere

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in…

Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and…
PR Newswire
13/06/2025

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece

PSMA-PET imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT[4] scan) thereby offering a new standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR[5]. Illuccix PSMA-PET will help fulfil a critical unmet need by facilitating access to timely and…
PR Newswire
13/06/2025

BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive…

"Exidavnemab is BioArctic's second disease modifying treatment for severe brain diseases, building on a similar scientific approach as Leqembi®. Both originate from our antibody platform, selectively targeting aggregated, toxic misfolded proteins. I am pleased that the interim safety review of our phase 2a study EXIST of exidavnemab showed a good safety and tolerability profile as expected, supporting progression into higher doses in both Parkinson's disease and MSA," says Gunilla…
PR Newswire
13/06/2025

ELFBAR and LOST MARY to reinforce industry leadership at Dubai World Vape Show…

The 2025 exhibition will showcase ELFBAR and LOST MARY's empowering user experience and product performance with R&D efforts, aimed at delivering the best possible smoking alternatives in adult users' cessation journey, enhancing supply chain efficiency, and maintaining stringent quality and safety standards. The 2025 exhibition will showcase ELFBAR and LOST MARY's empowering user experience and product performance with R&D efforts, aimed at delivering the best possible smoking…
PR Newswire
13/06/2025

Avextra Cannabis extract can potentially reduce symptom burden for late…

New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based MedicinesBensheim, Germany– 13th June 2025 – According to the World Health Organization, an estimated 56.8 million palliative care patients worldwide suffer from significant symptom burden every year. In palliative care — particularly for oncology patients — effective symptom management is essential to maintaining dignity, comfort, and quality of life in the final stages of...
Nasdaq GlobeNewswire
13/06/2025

Invitation to attend the extraordinary shareholders' meeting of the Company to…

REGULATED INFORMATIONJune 13, 2025, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH)Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the extraordinary shareholders' meeting of the Companyto be held on July 2, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held onWednesday, July 2, 2025 at 2:00 p...
Nasdaq GlobeNewswire
13/06/2025

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at…

Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO. Primary endpoints will includeneuropsychological assessments (CDR-SB, iADRS)andblood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported...
PR Newswire
13/06/2025

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment…

As per DelveInsight's analysis, approximately 60,000 allogeneic transplants and around 55,000 GvHD cases occurred in the 7MM in 2024. These numbers are projected to grow at a notable CAGR over the forecast period from 2025 to 2034. As per DelveInsight's analysis, approximately60,000allogeneic transplants and around55,000GvHD cases occurred in the 7MM in 2024. These numbers are projected to grow at a notable CAGR over the forecast period from 2025 to 2034. Corticosteroids like...
PR Newswire
12/06/2025

Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough…

Key Takeaways from the Cancer Pain Market Report Key Takeaways from the Cancer Pain Market Report Discover which therapies are expected to grab the major cancer pain market share @Cancer Pain Market Report Cancer Pain Overview Cancer pain is a common and often debilitating symptom experienced by individuals with cancer, resulting from a variety of causes such as tumor invasion into surrounding tissues, inflammation, nerve compression, or the side effects of treatments like...
PR Newswire
12/06/2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be...
Nasdaq GlobeNewswire
12/06/2025

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low…

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicitiesOf the 64 patients enrolled, 61 received treatment, resulting in a 5% attrition rate, significantly lower than industry benchmarks. 95% of patients were infused with fresh, stem-like early memory CD19 CAR-T cells, with 89% receiving treatment within 7 days, avoiding the need for...
Nasdaq GlobeNewswire
12/06/2025

Daewoong Pharmaceutical Launches NABOTA in Qatar, Expands Presence in…

The Gulf countries, which make up the Gulf Cooperation Council (GCC), are all oil-producing nations with high-income populations and rapidly increasing demand for aesthetic and cosmetic procedures. Cultural and linguistic similarities within the region contribute to active cross-border exchanges, enhancing synergy and market scalability. The Gulf countries, which make up the Gulf Cooperation Council (GCC), are all oil-producing nations with high-income populations and rapidly increasing…
PR Newswire
12/06/2025

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; June 12, 2025 –Genmab A/S(Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on...
Nasdaq GlobeNewswire
12/06/2025

Novo Nordisk to advance subcutaneous and oral amycretin for weight management…

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. “ We are very pleased that the feedback from regulatory authorities has...
Nasdaq GlobeNewswire
12/06/2025

First of Its Kind in the Region: KFSHRC Successfully Performs Endoscopic Sleeve…

RIYADH, Saudi Arabia, June12, 2025(GLOBE NEWSWIRE) -- In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully performed an endoscopic sleeve gastroplasty (ESG) on a patient who had previously undergone a kidney transplant, a case that requires meticulous management of immunosuppressive medications and the prevention of any complications that could jeopardize the transplanted organ...
Nasdaq GlobeNewswire
12/06/2025

Oxurion Receives Amended Transparency Notification from Atlas Special…

Leuven, BELGIUM – June 12, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 11, 2025, from Atlas Special…
Actusnews Wire
12/06/2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of May 31, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (June 12, 2025 - 6:00 pm)– As of May 31, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated...
Nasdaq GlobeNewswire
12/06/2025

KLEA HOLDING (ex VISIOMED GROUP) : Klea Holding adopts a new governance…

KLEA HOLDING (FR0013481835 - ALKLH), a group focused on the acquisition, development and digitalization of companies across multiple sectors, announces the successful holding of its Annual General Meeting[1] on 10 June 2025, at the end of which the change in governance announced on last 30 April[2] was approved…
Actusnews Wire
12/06/2025

DMS GROUP: INITIATION OF COVERAGE OF THE STOCK BY ODDO BHF

June 12, 2025 – 6:00 pm – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS and FR001400IAQ8 – DMSBS), a specialist in high-performance medical imaging systems for Digital Radiology and Bone Densitometry, announces the initiation of coverage of its stock by ODDO BHF. The study, entitled “Imaging2027 a return to basics that…
Actusnews Wire
12/06/2025

Ipsen - May 2025 - Monthly information relative to the total number of voting…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 31 May 202583,814,526Gross total* of...
Nasdaq GlobeNewswire
12/06/2025

LabConnect Selects Deloitte to Streamline Financial and Business Operations

"As we continue to expand our global footprint, this ERP modernization will enable LabConnect to better serve our clients with more responsive and efficient solutions," said David Rynders, Vice President, Global Corporate Controller. "LabConnect's partnership with Deloitte for the implementation of Microsoft Dynamics 365 Finance and Supply Chain strengthens our ability to deliver seamless, efficient, and scalable solutions to our customers around the world. By leveraging…
PR Newswire
12/06/2025

European Commission Grants Orphan Drug Designation to Florbetaben (18F) for…

Despite the observed rise in the prevalence and incidence of cardiac ATTR amyloidosis – and its high prevalence among patients with heart failure – the overall frequency in the general population remains below the threshold for orphan drug designation (five cases per ten thousand inhabitants of newly diagnosed patients). As a result, EMA granted orphan drug designation to florbetaben (18F) as a diagnostic agent for ATTR amyloidosis. Despite the observed rise in the prevalence and incidence of...
PR Newswire
12/06/2025

Lunit AI Used Again for Mass Screening During 2025 Hajj Season in Saudi Arabia

Hajj is one of the world's largest annual mass gatherings, drawing over 2 million pilgrims from more than 160 countries. During this high-risk period, the Saudi health authorities prioritize early detection of infectious diseases such as tuberculosis, pneumonia, and MERS. With hundreds of thousands of chest X-rays taken over just a few days, Lunit's AI successfully assisted healthcare teams on the ground by automatically analyzing chest X-rays to identify abnormalities, helping facilitate rapid…
PR Newswire
12/06/2025

Medical Waste Management Market worth US$59.42 billion by 2030 with 8.0% CAGR |…

For More Information and To Stay Updated on The Latest Developments in The Global Medical Waste Management Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=11650 For More Information and To Stay Updated on The Latest Developments in The Global Medical Waste Management Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=11650 Market Overview and Growth Trajectory: Medical Waste...
PR Newswire
12/06/2025
Altri  Comunicati